The literature on fusidic acid resistant Staphylococcus aureus strains is scarce in Iran, although the emergence of these strains in health care settings is increasing. This descriptive cross-sectional study was conducted on 68 fusidic acid resistant S. aureus strains to learn about the molecular characteristics and antimicrobial resistance of strains isolated from hospitalized patients. In the present study, the prevalence of resistance to fusidic acid in S. aureus isolates was 15.1%. Fusidic acid resistance determinative factors (fusB, fusC and fusD) were identified by multiplex PCR assay. To detect the existence of fusA and fusE determinants and their mutation status, amplifications and sequencing were performed. Molecular characterization of fusidic acid resistant isolates was investigated by SCCmec and spa typing methods. All strains were MRSA and multi drug resistant. Two (2.9%) and 31 (45.6%) isolates were resistant to vancomycin and mupirocin respectively. The SCCmec type IV was highly prevalent representing 50% followed by types III (51.5%), and SCCmec types II (13.2%). fusB, was the most predominant acquired gene (66.2%) followed by fusC (19.1%), and fusA (14.7%). The mutations in fusA were present in 10 isolates with 5 (50%) having L461K mutation showing fusidic acid MIC values of ≥256 μg ml−1 followed by H457Y (40%), and H457Q (10%) showing fusidic acid MIC values of 128 and 64 μg ml−1 respectively. Isolates were allocated to ten particular t030 (22.1%), t037 (14.6%), t408 (11.8%), t064 (11.8%), t008 (10.3%), t002 (8.8%), t005 (5.9%), t790 (5.9%), t318 (4.4%), and t018 (4.4%) spa types. fusA positive isolates were assigned to particular spa types t002 (60%), and t005 (40%). There may be be a spreading of fusidic acid resistance among MRSA, creating worrying public concern. This research notes the importance of adequate data of local prevalence of FA-resistant MRSA in Iran for taking appropriate measures to treat, control and reduce the incidence of these isolates.
Cheung GY, Bae JS, Otto M. Pathogenicity and virulence of Staphylococcus aureus. Virulence 2021; 12: 547–569. https://doi.org/10.1080/21505594.2021.1878688.
Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, Carugati M, et al. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat Rev Microbiol 2019; 17: 203–218. https://doi.org/10.1038/s41579-018-0147-4.
Foster TJ. Antibiotic resistance in Staphylococcus aureus. Current status and future prospects. FEMS Microbiol Rev 2017; 41: 430–449. https://doi.org/10.1093/femsre/fux007.
Tomlinson JH, Kalverda AP, Calabrese AN. Fusidic acid resistance through changes in the dynamics of the drug target. Proc Natl Acad Sci 2020; 117: 25523–25531. https://doi.org/10.1073/pnas.2008577117.
Al-Saleh A, Shahid M, Farid E, Bindayna K. Trends in methicillin-resistant Staphylococcus aureus in the Gulf Cooperation Council countries: antibiotic resistance, virulence factors and emerging strains. East Mediterr Health J 2022; 28: 434–443. https://doi.org/10.26719/emhj.22.042.
Besier S, Ludwig A, Brade V, Wichelhaus TA. Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mol Microbiol 2003; 47: 463–469. https://doi.org/10.1046/j.1365-2958.2003.03307.x.
Hajikhani B, Goudarzi M, Kakavandi S, Amini S, Zamani S, van Belkum A, et al. The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis. Antimicrob Resist Infect Control 2021; 10: 75. https://doi.org/10.1186/s13756-021-00943-6.
Boloki HA, Al-Musaileem WF, AlFouzan W, Verghese T, Udo EE. Fusidic acid resistance determinants in methicillin-resistant Staphylococcus aureus isolated in Kuwait hospitals. Med Princ Pract 2021; 30: 542–549. https://doi.org/10.1159/000518408.
Den Heijer CD, Van Bijnen EM, Paget WJ, Stobberingh EE. Fusidic acid resistance in Staphylococcus aureus nasal carriage strains in nine European countries. Future Microbiol 2014; 9: 737–745. https://doi.org/10.2217/fmb.14.36.
Goudarzi M, Kobayashi N, Dadashi M, Pantůček R, Nasiri MJ, Fazeli M, et al. Prevalence, genetic diversity, and temporary shifts of inducible clindamycin resistance Staphylococcus aureus clones in Tehran, Iran: a molecular–epidemiological analysis from 2013 to 2018. Front Microbiol 2020; 11: 663. https://doi.org/10.3389/fmicb.2020.00663.
Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; 31th Informational Supplement. CLSI document M100-S27. 1-56238-805-3; 2021.
Goudarzi M, Tayebi Z, Dadashi M, Miri M, Amirpour A, Fazeli M. Characteristics of community-acquired methicillin-resistant Staphylococcus aureus associated with wound infections in Tehran, Iran: high prevalence of PVL+ t008 and the emergence of new spa types t657, t5348, and t437 in Iran. Gene Rep 2020; 19, 100603. https://doi.org/10.1016/j.genrep.2020.100603.
Castanheira M, Watters AA, Mendes RE, Farrell DJ, Jones RN. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). J Antimicrob Chemother 2010; 65: 1353–1358. https://doi.org/10.1093/jac/dkq094.
Chen H-J, Hung W-C, Tseng S-P, Tsai J-C, Hsueh P-R, Teng L-J. Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 2010; 54: 4985–4991. https://doi.org/10.1128/AAC.00523-10.
Boye K, Bartels M, Andersen I, Møller J, Westh H. A new multiplex PCR for easy screening of methicillin-resistant Staphylococcus aureus SCCmec types I–V. Clin Microbiol Infect 2007; 13: 725–727. https://doi.org/10.1111/j.1469-0691.2007.01720.x.
Udo EE, Al-Sweih N, Mokaddas E, Johny M, Dhar R, Gomaa HH, et al. Antibacterial resistance and their genetic location in MRSA isolated in Kuwait hospitals, 1994-2004. BMC Infect Dis 2006; 6: 1–8. https://doi.org/10.1186/1471-2334-6-168.
Razeghi M, Saffarian P, Goudarzi M. Incidence of inducible clindamycin resistance and antibacterial resistance genes variability in clinical Staphylococcus aureus strains: a two-year multicenter study in Tehran, Iran. Gene Rep 2019; 16, 100411. https://doi.org/10.1016/j.genrep.2019.100411.
Zamani S, Mohammadi A, Hajikhani B, Abiri P, Fazeli M, Nasiri MJ, et al. Mupirocin-resistant Staphylococcus aureus in Iran: a biofilm production and genetic characteristics. Biomed Res Int 2022; 15: 1–9. https://doi.org/10.1155/2022/7408029.
Rahimi F, Bouzari M, Katouli M, Pourshafie MR. Antibiotic resistance pattern of methicillin resistant and methicillin sensitive Staphylococcus aureus isolates in Tehran, Iran. Jundishapur J Microbiol 2013; 6: 144–149. https://doi.org/10.5812/jjm.4896.
Hasani A, Sheikhalizadeh V, Hasani A, Naghili B, Valizadeh V, Nikoonijad AR. Methicillin resistant and susceptible Staphylococcus aureus: appraising therapeutic approaches in the Northwest of Iran. Iranian J Microbiol 2013; 5: 56–62.
Williamson DA, Carter GP, Howden BP. Current and emerging topical antibacterials and antiseptics: agents, action, and resistance patterns. Clin Microbiol Rev 2017; 30: 827–860. https://doi.org/10.1128/CMR.00112-16.
Shariati A, Dadashi M, Moghadam MT, van Belkum A, Yaslianifard S, Darban-Sarokhalil D. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis. Sci Rep 2020; 10: 1–16. https://doi.org/10.1038/s41598-020-69058-z.
Yu F, Liu Y, Lu C, Lv J, Qi X, Ding Y, et al. Dissemination of fusidic acid resistance among Staphylococcus aureus clinical isolates. BMC Microbiol 2015; 15: 1–6. https://doi.org/10.1186/s12866-015-0552-z.
Rijnders M, Wolffs P, Hopstaken R, Den Heyer M, Bruggeman C, Stobberingh E. Spread of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) in general practice patients in the south of The Netherlands. J Antimicrob Chemother 2012; 67: 1176–1180. https://doi.org/10.1093/jac/dkr590.
McLaws F, Larsen A, Skov R, Chopra I, O'Neill A. Distribution of fusidic acid resistance determinants in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55: 1173–1176. https://doi.org/10.1128/AAC.00817-10.
Chen C-M, Huang M, Chen H-F, Ke S-C, Li C-R, Wang J-H, et al. Fusidic acid resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in a Taiwanese hospital. BMC Microbiol 2011; 11: 1–8. https://doi.org/10.1186/1471-2180-11-98.
Zhao H, Wang X, Wang B, Xu Y, Rao L, Wan B, et al. The prevalence and determinants of fusidic acid resistance among methicillin-resistant Staphylococcus aureus clinical isolates in China. Front Med 2021; 8, 761894. https://doi.org/10.3389/fmed.2021.761894.
Castanheira M, Watters AA, Bell JM, Turnidge JD, Jones RN. Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007–2008. Antimicrob Agents Chemother 2010; 54: 3614–3617. https://doi.org/10.1128/AAC.01390-09.
Gülmez D, Sancak B, Ercis S, Karakaya J, Hascelik G. Investigation of SCCmec types and Panton-Valentine leukocidin in community-acquired and nosocomial Staphylococcus aureus strains: comparing skin and soft tissue infections to the other infections. Mikrobiyol Bul 2012; 46(3): 341–351.